ArchiMed Mergers and Acquisitions Summary

Private Equity Firm Profile

In the last 3 years, ArchiMed has acquired 13 companies. It has also invested in 4 others.

ArchiMed’s most common sectors for investment arelife science (37%) and medical products (25%) . The Firm’s most common investment types include buyout (lbo, mbo, mbi) (56%) and growth capital (20%). In total, ArchiMed has invested in 8 US states and 11 different countries. Its largest (disclosed) acquisition occurred in 2022 when it acquired Natus Medical for $1.1B.

In the last 3 years, ArchiMed has exited 7 companies. The Firm’s most common exit type is trade sale (89%). ArchiMed’s largest (disclosed) exit occurred in 2023 when it sold Polyplus-transfection SA for $2.7B.

Join Mergr to view ArchiMed’s full profile and discover more mega-sized private equity firm investors just like it.

M&A Summary

  • M&A Total Activity45
    • M&A Buy Activity36
    • M&A Sell Activity9
  • Total Sectors Invested 9
  • Total Countries Invested 11
  • M&A Buy/Sell Connections 10
  • M&A Advisors 4

ArchiMed

ArchiMed

Silex2 20F, 9 rue des Cuirassiers,,
Lyon, 69003
France
+33 4 81 11 35 33
www.archimed-group.eu
contact@archimed-group.eu

ArchiMed is a specialist French private equity firm focused on buyouts of and growth capital investments in European healthcare-oriented companies. The Firm looks to invest €10 million to €1 billion per transaction and specifically targets companies in the public health, care and wellness, biotech, and medical technology segments of the healthcare industry. ArchiMed was formed in 2014 and is headquartered in Lyon.


Investment Criteria

Sectors of Interest: Consumer Services, Healthcare Services, Life Science, Medical Products, Test/Measurement Equipment

Target Transaction Types: Buyout (LBO, MBO, MBI), Growth Capital, Recapitalization, Secondary Buyout, Stake Purchase

Geographic Preferences: United Kingdom, Western Europe, Eastern Europe, Nordic

Transaction Criteria Min Max
Target Revenue 5 100
Target EBITDA - -
Investment Size 10 1,000
Enterprise Value - -
values in millions of EUR

M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (4.0/yr) # 16 3 9 4 3 1 36
vol $92M $1.1B $312M $1.5B
Sell (1.4/yr) # 2 - - 5 2 - 9
vol $2.8B $2.8B
  45

Most Recent M&A

Company Date Value Type
Cellese 2024-04-09 - Buyout (LBO, MBO, MBI)
Irvine, California · www.anteage.com
Instem plc 2023-11-27 312M GBP Going Private
Stone, United Kingdom · www.instem.com
Symbio Proinnovera 2023-11-17 - Buyout (LBO, MBO, MBI)
Jefferson, New York · www.symbioresearch.com
Vita Health Group 2023-10-19 114M GBP Trade Sale
Bury Saint Edmunds, United Kingdom · www.vitahealthgroup.co.uk
Polyplus-transfection SA 2023-03-31 2.7B EUR Trade Sale
Illkirch, France · www.polyplus-transfection.com
WiQo 2023-03-09 - Buyout (LBO, MBO, MBI)
Milan, Italy · www.wiqo.com
Xpress Biologics SA 2022-12-07 - Trade Sale
Milmort, Belgium · www.xpress-biologics.com
Micromed S.p.A. 2022-12-02 - Trade Sale
Treviso, Italy · www.micromedgroup.com
PlasmidFactory GmbH 2022-10-07 - Growth Capital
Bielefeld, Germany · www.plasmidfactory.com
Bomi Italia S.p.A. 2022-08-08 - Trade Sale
Spino d’Adda, Italy · www.bomigroup.com
View All >>

Portfolio M&A

Company Acquired Add-On/Sale Date #
Natus Medical, Inc. 2022-07-21 Micromed S.p.A. 2022-12-02 1
Middleton, Wisconsin · www.natus.com Treviso, Italy · www.micromedgroup.com
Direct Healthcare Group 2019-12-09 Handicare AS - Patient Handling Division 2020-04-09 3
Caerphilly, United Kingdom · www.directhealthcaregroup.com Kista, Sweden

M&A by Sector

Sector Current # Value All-time # Value
Life Science 11 (42%) - 13 (36%) -
Medical Products 8 (31%) 1.1B (78%) 9 (25%) 1.1B (73%)
Consumer Products 2 (8%) - 4 (11%) -
Healthcare Services - - 3 (8%) 79M (5%)
Software 1 (4%) - 2 (6%) 14M (1%)
Business Services 2 (8%) - 2 (6%) -
Information Technology 1 (4%) 312M (22%) 1 (3%) 312M (21%)
Technology Hardware 1 (4%) - 1 (3%) -
Test/Measurement Equipment - - 1 (3%) -
Total 26 $1.4B 36 $1.5B

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 8 (31%) 1.1B (78%) 9 (25%) 1.1B (74%)
  Wisconsin 2 (8%) 1.1B (78%) 2 (6%) 1.1B (73%)
  New York 1 (4%) - 1 (3%) -
  Florida 1 (4%) - 1 (3%) -
  Colorado 1 (4%) - 1 (3%) -
  California 1 (4%) - 1 (3%) -
  Arizona 1 (4%) - 1 (3%) -
  Ohio 1 (4%) - 1 (3%) -
  Georgia - - 1 (3%) 14M (1%)
France 4 (15%) - 7 (19%) -
Italy 3 (12%) - 6 (17%) 79M (5%)
United Kingdom 3 (12%) 312M (22%) 4 (11%) 312M (21%)
Germany 3 (12%) - 3 (8%) -
Canada 2 (8%) - 2 (6%) -
  Quebec 1 (4%) - 1 (3%) -
  Ontario 1 (4%) - 1 (3%) -
Spain 1 (4%) - 1 (3%) -
Netherlands 1 (4%) - 1 (3%) -
Switzerland 1 (4%) - 1 (3%) -
Austria - - 1 (3%) -
Belgium - - 1 (3%) -
Total 26 $1.4B 36 $1.5B

Acquisitions by Deal Type

Type Current # Value All-time # Value
Buyout (LBO, MBO, MBI) 14 (54%) - 20 (56%) 14M (1%)
Growth Capital 5 (19%) - 7 (19%) -
Secondary Buyout 4 (15%) - 5 (14%) -
Going Private 2 (8%) 1.4B (100%) 3 (8%) 1.5B (99%)
Recapitalization 1 (4%) - 1 (3%) -
Total 26 $1.4B 36 $1.5B

Exits by Deal Type

Type Total # Value
Trade Sale 5 (56%) 114M (4%)
Trade Sale - Public Company 3 (33%) 2.7B (96%)
Secondary Sale 1 (11%) -
Total 9 $2.8B

Top M&A Advisors

Financial Deals
Jefferies
 1
Legal Deals
Bird & Bird
 1
Latham & Watkins
 1
Gianni & Origoni
 1

Deal Values

buy # Total
> $1B 1 $1.1B
$100M to $1B 1 $312M
< $100M 2 $92M
TOTAL $1.5B
Largest Natus Medical, Inc.
$1.1B (2022-07-21)
sell # Total
> $1B 1 $2.7B
$100M to $1B 1 $114M
TOTAL $2.8B
Largest Polyplus-transfection SA
$2.7B (2023-03-31)

M&A Connections

Deals
Acquired from
Investor(s)
14%
5 (14%)
Exited to
Investor(s)
11%
1 (11%)
Strategic(s)
89%
8 (89%)

Investor Summary

Investor Type

Private Equity Firm

Size

Mega

PE Assets

8.0B EUR

Established

2014

Specialist/Generalist

Specialist

Leadership

Denis Ribon

Co-Founder & Managing Partner

Vincent Guillaumot

Founding Partner & Managing Partner

Thierry Picard

Chief Digital Officer

André-Michel Ballester

Managing Partner

Antoine Faguer

Partner

FAQ

When was ArchiMed founded?

ArchiMed was founded in 2014.

What type of investor is ArchiMed?

ArchiMed is a private equity firm.

Where is ArchiMed headquartered?

ArchiMed is headquartered in Lyon, France.

How much capital does ArchiMed have under management?

ArchiMed has 8.0B EUR under management.

 Subscribe to unlock this and 208,055
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 201K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal